The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer.
 
Maira Soto
Employment - Apexigen; Kodiak Sciences
Research Funding - Apexigen
 
Erin L Filbert
Employment - Apexigen
Stock and Other Ownership Interests - Apexigen
Research Funding - Apexigen
Patents, Royalties, Other Intellectual Property - Apexigen (Inst)
 
Hai Yang
No Relationships to Disclose
 
Li Zhang
Consulting or Advisory Role - Raydiant Oximetry
Travel, Accommodations, Expenses - Dendreon
 
Stephanie Starzinski
No Relationships to Disclose
 
Alec Starzinski
No Relationships to Disclose
 
Alexander Cheung
Employment - Genentech (I)
 
Tony Li
No Relationships to Disclose
 
Frank J. Hsu
Employment - Apexigen; Oncternal Therapeutics, Inc
Leadership - Apexigen; Oncternal Therapeutics, Inc
Stock and Other Ownership Interests - Abbvie; Amgen; Apexigen; Immune Design
Patents, Royalties, Other Intellectual Property - Genzyme (Inst); immune Design (Inst); Stanford University (Inst)
Travel, Accommodations, Expenses - Apexigen; Oncternal Therapeutics, Inc
 
Andrew H. Ko
Honoraria - BioAscent; Clinical Care Options; Gerson Lehrman Group; Medscape; MJH Life Sciences; Research to Practice
Consulting or Advisory Role - ERYTECH Pharma; Five Prime Therapeutics; Imugene; Ipsen; Roche/Genentech; Signatera; SynCoreBio; Syros Pharmaceuticals; Turning Point Therapeutics; Tyme
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CrystalGenomics (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)
 
Lawrence Fong
Stock and Other Ownership Interests - Actym Therapeutics; Alector; Atreca; BioAtla; Bolt Biotherapeutics; ImmunoGenesis; Nutcracker Therapeutics, Inc.; RAPT Therapeutics; Senti Biosciences; SOTERIA Precision Medicine; Sutro Biopharma
Consulting or Advisory Role - Alector; AstraZeneca; Atreca; BioAtla; Bolt Biotherapeutics; Bristol-Myers Squibb; Dendreon; EMD Serono; Innovent Biologics; Janssen Oncology; Merck; Nutcracker Therapeutics, Inc.; RAPT Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Bridget P Keenan
Employment - Astellas Pharma (I)
Research Funding - Partner Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech/Roche